The Latest Breaking News from Teleflex

Despite Teleflex’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Teleflex is set to report its third-quarter earnings by the end of this month, with analysts projecting a slight decline in its bottom line.

Over the past 3 months, 12 analysts have published their opinion on Teleflex (NYSE:TFX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

The threat of stagflation looms, with inflation rampant and the economy likely to slow down. Bank of America has appropriate investing ideas.

Despite the prevailing bearish investor sentiment, the healthcare industry is expected to continue growing amid an increase in global chronic diseases, rapid medical advancements, and an aging population. The stocks of quality healthcare companies Bausch Health (BHC), Teleflex (TFX), Abcam (ABCM), and Integra LifeSciences (IART) are currently trading near their…

Upgrades

According to Benzinga Pro, during Q1, Teleflex (NYSE:TFX) earned $77.14 million, a 39.77% increase from the preceding quarter. Teleflex's sales decreased to $641.72 million, a 15.78% change since Q4.

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance. 

Needham has decided to maintain its Buy rating of Teleflex (NYSE:TFX) and lower its price target from $400.00 to $355.00. Shares of Teleflex are trading down 1.62% over the last 24 hours, at $290.71 per share. A move to $355.00 would account for a 22.11% increase from the current share…